Performance analysis of Silexion Therapeutics (SLXN)
Annual Return
Since Aug 16, 2024, SLXN has had an average annual return of -97.23%, underperforming the benchmark SPY, which returned +17.77% annual.
| 2026 | 2025 | 2024 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -86.30% | -93.62% | -88.55% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.11% | -5.71% | -25.76% | -53.06% | -17.39% | -47.37% | +0% | -86.30% | |||||
| 2025 | -5.41% | -43.67% | +2.79% | -10.53% | +5.70% | -22.09% | +22.94% | -51.06% | -53.60% | -2.33% | -14.29% | -32.41% | -93.62% |
| 2024 | -25.13% | -64.03% | -43.82% | +5.09% | -27.99% | -88.55% |
Drawdown analysis of Silexion Therapeutics (SLXN)
The maximum drawdown for the SLXN was -99.92%, occurring on Jul 13, 2026. This drawdown has not yet recovered.
The current SLXN drawdown is -99.91%.
Since Aug 16, 2024 SLXN has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 1 time
- 20% or more: 1 time
- 10% or more: 1 time
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.92% | Aug 19, 2024 | 474 | Jul 13, 2026 | Ongoing | Ongoing | Ongoing |